For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Other symptoms may mimic signs of poor circulation like pins and needles, cold extremities, pale or blue skin, muscle ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Boston Scientific (NYSE: BSX) announced on social media that it completed its previously announced acquisition of Bolt ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...